PT  - JOURNAL ARTICLE
AU  - Destras, G.
AU  - Bal, A.
AU  - Simon, B.
AU  - Lina, B.
AU  - Josset, L.
TI  - Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients
AID  - 10.1101/2022.04.08.22273513
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.08.22273513
4099  - http://medrxiv.org/content/early/2022/04/16/2022.04.08.22273513.short
4100  - http://medrxiv.org/content/early/2022/04/16/2022.04.08.22273513.full
AB  - After monoclonal antibody sotrovimab implementation, Rockett et al have warned on March 9th about two resistant mutations in the spike at position 337 and 340 occurring within the first week in four immunocompromised patients infected by a Delta variant and resulting in viable infection up to 25 days. As sotrovimab is currently the only effective treatment against BA.1 lineage of Omicron variant, we investigated the presence of these mutations in our 22,908 Omicron sequences performed from December 2021 to March 2022.Among 25 Omicron sequences with S:337 and S:340 substitutions, 9 were reported in six patients who had available clinical data and a follow up. All were immunicompromised, and presented a rapid selection of these mutations after sotrovimab monotherapy infusion.With these findings, we underscore that although these mutations are rare, they have been exclusively reported in immunocompromised patients treated with sotrovimab. We urge to consider monoclonal antibody as monotherapy in immunocompromised patients as a risk for escape mutants selection.Competing Interest StatementB.L. is a member of the French Scientific Commitee for SARS-CoV-2. All authors have nothing to disclose.Funding StatementThis study was performed in the field of the global surveillance of SARS-CoV-2 virus performed by the WHO and by the Centre National de Reference des Virus des Infections Respiratoires.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples used in this study were collected as part of an approved ongoing surveillance conducted by the National Reference Center of Hospices Civils de Lyon, Lyon, France. The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78/17 on 06 January 1978 and Decret 2019/536 on 29 May 2019). Samples were collected for regular clinical management, with no additional samples for the purpose of this study. Patients were informed of the research and their nonobjection approval was confirmed. This study was approved by the ethics committee of HCL and registered on the HCL database of non-interventional studies (AGORA N41).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.